Sign inJoin waitlistJoin the waitlist

KB

Kimberly Blackwell

Adjunct Professor in the Department of Medicine · Duke University Hospital

Credentials: · ·

History

Duke University Hospital
Present

Hematology and Medical Oncology
Duke University Hospital
1997–2000
Internal Medicine
Duke University Hospital
1994–1997
Mayo Clinic College of Medicine and Science
1991–1994
Doctor of Medicine
1990–1994

Research

Trastuzumab emtansine for HER2-positive advanced breast cancer
New England Journal of Medicine · 2012 · 2,970 citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
New England Journal of Medicine · 2016 · 1,581 citations
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
Journal of Clinical Oncology · 2010 · First of 12 authors · Corresponding · 720 citations

PM
Paul Marcom
16 papers
Carey Anders
12 papers
Eric Winer
10 papers
ZV
Zeljko Vujaskovic
10 papers
EH
Erika Hamilton
9 papers · 9 as a fellow
Gretchen Kimmick
8 papers
IK
Ian Krop
8 papers
Michael Morse
8 papers
NS
Neil Spector
8 papers
Harold Burstein
7 papers
Herbert Lyerly
7 papers
Hope Rugo
7 papers

Grants

Antiestrogenic Effects on Tumor Angiogenesis
National Cancer Institute · K08
Contact PI · $653.2K · Duke University
2001–2006

Clinical trials

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer
Principal investigator · Terminated · Phase 1
Kimberly Blackwell
2017–2018
Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC
Principal investigator · Withdrawn · Phase 1
Duke University
2017–2018
Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer
Principal investigator · Terminated
Duke University
2016–2018
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Principal investigator · Withdrawn · Phase 1
Duke University
2015–2017